Evidence map›Paper›PMID 24375395›Full record

Trial reportMedical oncology (Northwood, London, England)2014

The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer.

Marina Petrović, Zoran Bukumirić, Vladimir Zdravković, Slobodanka Mitrović, Henry Dushan Atkinson, Vladimir Jurišić

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05010863 (Gastric Cancer Marker Detection and Its Kit Development), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05010863 recruitingnot on this mapstarted 2021, after this paper: background citation

Gastric Cancer Marker Detection and Its Kit Development

Typeobservational_patient_registrySponsorSecond Affiliated Hospital of Wenzhou Medical UniversityRan2021 to 2030Enrolled530ConditionsGastric CancerArmsBlood collection
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer.Bulletin of experimental biology and medicine · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Circulating GRP78 acts as a biomarker in the early diagnosis of lung cancer.International journal of clinical and experimental pathology · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Marina PetrovićFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Zoran Bukumirić
Vladimir Zdravković
Slobodanka Mitrović
Henry Dushan Atkinson
Vladimir Jurišić
University of Kragujevac · RSNorth Middlesex Hospital · GBUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the most common cancer, and small-cell lung cancer (SCLC) accounts for around 20 % of lung cancers. SCLC has a neuroendocrine cellular origin, and the tumor cells usually express neuroendocrine markers. There have been major recent advances in the management of SCLC, and multimodal approaches are now the norm. An improved knowledge of the prognostic variables would assist in defining which patients were better candidates to receive these newer intensive therapies. This single-center retrospective study of 97 previously untreated and histologically proven SCLC patients analysed the circulating neuroendocrine markers chromogranin A (CGA), pro-gastrin-releasing peptide (ProGRP), and neuron-specific enolase (NSE) in addition to the other more classical variables. Fifty patients had limited-stage disease and 47 had extensive disease. Sixty patients had an ECOG performance status (PS) of 0-1 and 37 had PS 2-4. Median survival for the whole study population was 13 months. Univariate analysis and univariate Cox regression modeling found a statistically significant association between survival and PS, disease stage, and CGA, ProGRP, and NSE levels. Age and sex were not prognostic. A shorter survival time was found in patients with a PS equal to or >2, extensive stage disease, a serum CGA level >56 ng/ml, a serum ProGRP level >58 pg/ml, and a serum NSE level >19 ng/ml. This study has found that there is a potential role for ProGRP, NSE, and CGA in both staging and prognosing survival in SCLC patients.

Indexed as

AdultAgedBiomarkers, TumorChromogranin AFemaleFollow-Up StudiesGastrin-Releasing PeptideHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingPhosphopyruvate HydratasePrognosisRetrospective StudiesSmall Cell Lung CarcinomaBiomarkers, TumorCHGA protein, humanChromogranin AGastrin-Releasing PeptidePhosphopyruvate Hydratase

Identifiers

PMID24375395
OpenAlexW2050540111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.